Detalles de la búsqueda
1.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 24(12): 1359-1374, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926100
2.
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Breast Cancer Res
; 25(1): 39, 2023 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37046348
3.
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Lancet Oncol
; 21(11): 1443-1454, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33152284
4.
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Lancet Oncol
; 20(7): 1023-1034, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31160249
5.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Breast Cancer Res
; 22(1): 2, 2019 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31892336
6.
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
Breast Cancer Res Treat
; 171(1): 65-74, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29766362
7.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 18(7): 929-945, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28600210
8.
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
Breast Cancer Res
; 18(1): 39, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27036195
9.
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
BMC Cancer
; 16(1): 770, 2016 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27716125
10.
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Lancet Oncol
; 13(4): 420-32, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22265698
11.
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Lancet Oncol
; 12(2): 127-36, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21236730
12.
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Clin Cancer Res
; 28(7): 1323-1334, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35165099
13.
Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.
BMC Med Res Methodol
; 11: 4, 2011 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-21223539
14.
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
Eur J Cancer
; 153: 242-256, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34256319
15.
Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom.
Clin Infect Dis
; 51(12): e95-104, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21067352
16.
Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment.
JCO Precis Oncol
; 32019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914010
17.
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
J Clin Oncol
; 37(3): 178-189, 2019 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30523750
18.
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
Stat Methods Med Res
; 27(3): 765-784, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27114326
19.
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
Nat Commun
; 9(1): 896, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29497091
20.
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
JNCI Cancer Spectr
; 2(2): pky005, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31360844